EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation

Jing Lu, Jie Gao, Jing Sun, Haiping Wang, Huijuan Sun, Qian Huang, Yao Zhang, Shuo Zhong

Frontiers in Pharmacology · 28.07.2023 · 14

DOI: 10.3389/fphar.2023.1106339 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Frontiers in Pharmacology, online erschienen am 28.07.2023. Verfasst von Jing Lu und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Apolipoprotein A-I (apoA-I), 90% of which is present in high-density lipoprotein (HDL), is the main constituent of HDL, has anti-inflammatory and anti-oxidant properties, and has received extensive attention in anti-atherosclerosis. Yet little is known about apoA-I ’s role in peritoneal dialysis. In this study, by analyzing PD patients ( n = 81), we found that decreased apoA/HDL-C ratio is significantly associated with rapid decline in peritoneal function. Further studies were performed in animal experiments to determine the ascendancy of apolipoprotein A-I mimetic peptide (D-4F) on peritoneum, we found that D-4F administration reduced peritoneal fibrosis and peritoneal endothelial mesenchymal transformation (EMT) induced by high glucose peritoneal dialysate, such as N-cadherin, Fibronectin, Vimentin, and α-smooth muscle actin (α-SMA) expression decreased. In mechanism, D-4F can significantly inhibit Smad2/3 phosphorylation, which is the major pathway leading to fibrosis. Furthermore, D-4F treatment inhibited NADPH oxidase and thiobarbituric acid reactive substances (TBARS) expression, increased the activity of certain enzymes, such as superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px). Finally, treatment with D-4F inhibits the expression of interleukins-6(IL-6), Interleukin-1β(IL-1β), and tumor necrosis factor-α(TNF-α). Taken together, based on the above research evidence, apoA-I and its peptide mimic may regulate the oxidative stress, TGF- β1/Smads signaling pathway and inflammatory response to reduce peritoneal fibrosis due to peritoneal dialysis.

Schlagwörter

Stichwörter der Autor:innen

D-4F, oxidative stressapolipoprotein A-Iinflammationinflammation peritoneal dialysisperitoneal dialysisperitoneal fibrosis

Autor:innen und Institutionen

  • Department of Nephrology, Shandong Provincial Hospital Affiliated to Shandong First Medical University, Jinan, China.
  • Jinzhou First People's Hospital, Dalian, China.

Zitieren

APA

Lu, J., Gao, J., Sun, J., Wang, H., Sun, H., Huang, Q., Zhang, Y., & Zhong, S. (2023). Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation. Frontiers in Pharmacology, 14. https://doi.org/10.3389/fphar.2023.1106339

Vancouver

Lu J, Gao J, Sun J, Wang H, Sun H, Huang Q, et al. Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation. Frontiers in Pharmacology. 2023;14. doi:10.3389/fphar.2023.1106339

BibTeX
@article{Lu2023,
  author = {Lu, Jing and Gao, Jie and Sun, Jing and Wang, Haiping and Sun, Huijuan and Huang, Qian and Zhang, Yao and Zhong, Shuo},
  title = {Apolipoprotein A-I attenuates peritoneal fibrosis associated with peritoneal dialysis by inhibiting oxidative stress and inflammation},
  journal = {Frontiers in Pharmacology},
  year = {2023},
  volume = {14},
  doi = {10.3389/fphar.2023.1106339}
}
Kostenlos starten →